TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

被引：0
|
作者：
Cabel, Luc
Loirat, Delphine
Babau, Jerome Martin
Bello, Diana
Pierga, Jean-Yves
Lerebours, Florence
Ezzili, Cyrine
Berger, Frederique
Bidard, Francois Clement
机构：
[1] Inst Curie, Paris, France
[2] Inst Curie, St Cloud, France
[3] Inst Curie, Med Oncol Dept & D3i, Paris, France
[4] Hop Prive Cotes Armor, Plerin, France
[5] Inst Curie, Med Oncol Dept, St Cloud, France
[6] Inst Curie Paris, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1142
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer
    August Garin
    Alexey Manikhas
    Mikhail Biakhov
    Mikhail Chezhin
    Tatiana Ivanchenko
    Kurt Krejcy
    Vera Karaseva
    Sergey Tjulandin
    Breast Cancer Research and Treatment, 2008, 110 : 309 - 315
  • [32] A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer
    Garin, August
    Manikhas, Alexey
    Biakhov, Mikhail
    Chezhin, Mikhail
    Ivanchenko, Tatiana
    Krejcy, Kurt
    Karaseva, Vera
    Tjulandin, Sergey
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 110 (02) : 309 - 315
  • [33] Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
    Denise A. Yardley
    Dianna L. Shipley
    Nancy W. Peacock
    Mythili Shastry
    Rajiv Midha
    Victor M. Priego
    John D. Hainsworth
    Breast Cancer Research and Treatment, 2015, 152 : 557 - 567
  • [34] A phase II neoadjuvant study of cisplatin/paclitaxel with or without RAD001 in patients with triple-negative (TN) locally advanced breast cancer (BC).
    Mayer, I. A.
    Meszoely, I. M.
    Sanders, M.
    Shyr, Y.
    Abramson, V. G.
    Means-Powell, J. A.
    Chakravarthy, A. B.
    Arteaga, C. L.
    Pietenpol, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
    Yardley, Denise A.
    Shipley, Dianna L.
    Peacock, Nancy W.
    Shastry, Mythili
    Midha, Rajiv
    Priego, Victor M.
    Hainsworth, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 557 - 567
  • [36] A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer.
    Tolaney, Sara M.
    Guo, Hao
    Barry, William Thomas
    Larrabee, Katherine
    Brock, Jane E.
    Wagle, Nikhil
    Van Allen, Eliezer Mendel
    Paweletz, Cloud
    Ivanova, Elena
    Janne, Pasi A.
    Overmoyer, Beth
    Wright, John Joseph
    Shapiro, Geoffrey
    Winer, Eric P.
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
    Fenn, Kathleen
    Maurer, Matthew
    Lee, Shing M.
    Crew, Katherine D.
    Trivedi, Meghna S.
    Accordino, Melissa K.
    Hershman, Dawn L.
    Kalinsky, Kevin
    CLINICAL BREAST CANCER, 2020, 20 (01) : 80 - 86
  • [38] Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S17 - S18
  • [39] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Joyce O’Shaughnessy
    Adam Brufsky
    Hope S. Rugo
    Sara M. Tolaney
    Kevin Punie
    Sagar Sardesai
    Erika Hamilton
    Delphine Loirat
    Tiffany Traina
    Roberto Leon-Ferre
    Sara A. Hurvitz
    Kevin Kalinsky
    Aditya Bardia
    Stephanie Henry
    Ingrid Mayer
    Yanni Zhu
    See Phan
    Javier Cortés
    Breast Cancer Research and Treatment, 2022, 195 : 127 - 139
  • [40] Design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Berrak, E.
    Atkan, G.
    Song, J.
    Almonte, A.
    Karantza, V.
    Yuan, R.
    CANCER RESEARCH, 2016, 76
12345